These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39052748)

  • 1. Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
    Elliot ER; Polli JW; Patel P; Garside L; Grove R; Barnett V; Roberts J; Byrapuneni S; Crauwels H; Ford SL; Van Solingen-Ristea R; Birmingham E; D'Amico R; Baugh B; van Wyk J
    J Infect Dis; 2024 Jul; 230(1):e34-e42. PubMed ID: 39052748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
    Oka S; Holohan V; Shirasaka T; Choi JY; Kim YS; Chamay N; Patel P; Polli JW; Ford SL; Crauwels H; Garside L; D'Amico R; Latham C; van Solingen-Ristea R; Baugh B; van Wyk J
    HIV Med; 2024 Mar; 25(3):381-390. PubMed ID: 38147871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
    Chounta V; Snedecor SJ; Wu S; Van de Velde N
    BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
    Overton ET; Richmond G; Rizzardini G; Thalme A; Girard PM; Wong A; Porteiro N; Swindells S; Reynes J; Noe S; Harrington C; Español CM; Acuipil C; Aksar A; Wang Y; Ford SL; Crauwels H; van Eygen V; Van Solingen-Ristea R; Latham CL; Thiagarajah S; D'Amico R; Smith KY; Vandermeulen K; Spreen WR
    Clin Infect Dis; 2023 May; 76(9):1646-1654. PubMed ID: 36660819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
    Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
    Cutrell AG; Schapiro JM; Perno CF; Kuritzkes DR; Quercia R; Patel P; Polli JW; Dorey D; Wang Y; Wu S; Van Eygen V; Crauwels H; Ford SL; Baker M; Talarico CL; Clair MS; Jeffrey J; White CT; Vanveggel S; Vandermeulen K; Margolis DA; Aboud M; Spreen WR; van Lunzen J
    AIDS; 2021 Jul; 35(9):1333-1342. PubMed ID: 33730748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
    Jonsson-Oldenbüttel C; Ghosn J; van der Valk M; Florence E; Vera F; De Wit S; Rami A; Bonnet F; Hocqueloux L; Hove K; Ait-Khaled M; DeMoor R; Bontempo G; Latham CL; Gutner CA; Iyer S; Gill M; Czarnogorski M; D'Amico R; van Wyk J
    J Acquir Immune Defic Syndr; 2024 Aug; 96(5):472-480. PubMed ID: 38985445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
    Orkin C; Schapiro JM; Perno CF; Kuritzkes DR; Patel P; DeMoor R; Dorey D; Wang Y; Han K; Van Eygen V; Crauwels H; Ford SL; Latham CL; St Clair M; Polli JW; Vanveggel S; Vandermeulen K; D'Amico R; Garges HP; Zolopa A; Spreen WR; van Wyk J; Cutrell AG
    Clin Infect Dis; 2023 Nov; 77(10):1423-1431. PubMed ID: 37340869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
    Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
    van Welzen BJ; Van Lelyveld SFL; Ter Beest G; Gisolf JH; Geerlings SE; Prins JM; Van Twillert G; Van Nieuwkoop C; Van der Valk M; Burger D; Wensing AMJ
    Clin Infect Dis; 2024 Jul; 79(1):189-195. PubMed ID: 38207125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
    Swindells S; Lutz T; Van Zyl L; Porteiro N; Stoll M; Mitha E; Shon A; Benn P; Huang JO; Harrington CM; Hove K; Ford SL; Talarico CL; Chounta V; Crauwels H; Van Solingen-Ristea R; Vanveggel S; Margolis DA; Smith KY; Vandermeulen K; Spreen WR
    AIDS; 2022 Feb; 36(2):185-194. PubMed ID: 34261093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
    Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR
    AIDS; 2022 Feb; 36(2):195-203. PubMed ID: 34652287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
    Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
    Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
    Gutner CA; Hocqueloux L; Jonsson-Oldenbüttel C; Vandekerckhove L; van Welzen BJ; Slama L; Crusells-Canales M; Sierra JO; DeMoor R; Scherzer J; Ait-Khaled M; Bontempo G; Gill M; Patel N; D'Amico R; Hove K; Baugh B; Barnes N; Hadi M; Low EL; Anand SB; Hamilton A; Garges HP; Czarnogorski M
    J Int AIDS Soc; 2024 Jul; 27(7):e26243. PubMed ID: 38978405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
    Scheibe K; Urbańska A; Serwin K; Parczewski M
    Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.